Ananthakrishnan A, Kwon J, Raffals L, et al. Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol. 2015;13:1197–1200.
Belendiuk K, Baldini L, Bonn-Miller M. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:1–10.
Ahmed W, Katz S. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol. 2016;12:668–679.
Allegretti J, Courtwright A, Lucci M, Korzenik J, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814.
Naftali T, Schleider B, Dotan I, Lansky E, Benjaminov F, Konikoff F. Cannabis induces a clinical response in patients with Crohn’s disease; a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280.
Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.
Storr M, Devlin S, Kaplan G, Panaccione R, Andrews C. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.
Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.
Long M, Kappelman M, Martin C, et al. Development of an internet-based cohort of patients with inflammatory bowel disease (CCFA partners); Methodology and initial results. Inflamm Bowel Dis. 2012;18:2099–2106.
Thia K, Faubion W, Loftus E, Persson T, Persson A, Sandborn W. Short CDAI: development and validation of a shortened and simplified Crohn’s disease activity index. Inflamm Bowel Dis. 2011;17:105–111.
Jowett S, Seal C, Phillips E, Gregory W, Barton J, Welfare M. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003;38:164–171.
Irvine E, Zhou Q, Thompson A. The short inflammatory bowel disease questionnaire; a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.
Cella D, Yount S, Rothrock N. The patient-reported outcomes measurement information system (PROMIS): progress of an NIIH roadmap cooperative group during tis first two years. Med Care. 2007;45:S3–S11.
Kappelman M, Long M, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1315–1323.
Yost K, Eton D, Garcia S, Cella D. Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507–516.
Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.
de Vries M, van Rijckevorsel D, Vissers K, Wilder-Smith O, van Goor H. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol. 2017;15:1079–1086.
Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. Mucosal Immunol. 2011;4:574–583.
Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85:1306–1316.
Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med. 2009;87:1111–1121.
Storr M, Keenan C, Zhang H, Patel K, Makriyannis A, Sharkey K. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678–1685.
Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med. 2008;10:678–679.
Wright K, Duncan M, Sharkey K. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263–270.
Izzo A, Sharkey K. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126:21–38.
Sharkey K, Wiley J. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016;151:252–266.
Chaudhry H, Hengerer A, Snyder G. Medical board expectations for physicians recommending marijuana. J Am Med Assoc. 2016;316:577–578.